- Blood Sugar
- Clinical Studies
- Complementary Medicine
- Diabetes and Men
- Erectile Dysfunction
- Food and Nutrition
- Insulin Pumps
- Meters and Test Strips
- Product Recalls
- Type 1
- Type 2
- Weight Loss Surgery
Archive - 05 - 2014
May 26, 2014 (Medscape) -- The glucose-lowering drug liraglutide (Victoza, Novo Nordisk) promotes weight loss in overweight and obese people who don't have diabetes, according to the results of the multinational SCALE — Obesity and Prediabetes trial, presented here at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific and Clinical Congress. The injectable glucagonlike peptide-1 (GLP-1) agonist performed significantly better than placebo, producing weight loss comparable to that of already-approved weight-loss drugs in other trials, said Xavier Pi-Sunyer, MD, professor of medicine at Columbia University College of Physicians and Surgeons in New York City and codirector of the New York Obesity Nutrition Research Center. "Patients lost 8% of their body weight from baseline," he told Medscape Medical News. "That's as good as any drug out there. It's better than anything except [phentermine-topiramate], and it's about as good as [phentermine-topiramate]. I think it stacks up pretty well." On September 11, 2014, a US Food and Drug Administration advisory panel is scheduled to review liraglutide 3.0 mg — a higher dose than the approved 1.8-mg dose used for diabetes — for the new obesity indication. There was significantly more nausea and vomiting with liraglutide compared with placebo in SCALE, but it resolved with time. Also, a slightly elevated risk for pancreatitis and gallbladder disorders was seen among patients randomized to liraglutide compared with placebo. "The net effect was under 1% but was slightly more for the drug vs placebo group. It is being investigated and people are being followed," said Dr. Pi-Sunyer. Low rates of these events preclude any conclusion about causation, Farhad Zangeneh, MD, director of the Endocrine, Diabetes, and Osteoporosis Clinic, Sterling, Virginia, told Medscape Medical News. "Obesity and diabetes [themselves] cause pancreatitis and gallbladder issues. There's a lot of background noise," he said. Dr. Zangeneh was not involved in the study. Weight Loss The study enrolled 3731 individuals with a body mass index (BMI) =30 kg/m2 or =27 kg/m2 with 1 or more comorbidities. Participants were randomized 2:1 to receive once-daily subcutaneous liraglutide 3.0 mg or placebo, along with diet and exercise. Of the 2590 patients who completed the 56-week study, 78.5% were female with a mean age of 45 years, mean body weight of 106 kg, and mean BMI of 38 kg/m2. Nearly two-thirds had prediabetes. More patients on liraglutide completed the study than those on placebo (72% vs 64%). At week 56, the liraglutide group had lost 8.0% of their body weight (8.4 kg), compared with 2.6% (2.8 kg) in the placebo group (P < .0001). The proportion of patients who lost 5% or more of their body weight was 64% with liraglutide 3.0 mg vs 27% with placebo (P < .0001); 33% and 10%, respectively, lost more than 10% of their body weight. Weight loss was independent of prediabetes status or baseline BMI, Dr. Pi-Sunyer reported. The liraglutide group experienced blood-pressure drops of 2.82 mm Hg (systolic) and 0.89 mm Hg (diastolic). Lipid profiles improved as well, with increases in HDL cholesterol and reductions in LDL and VLDL cholesterol and triglycerides (overall significance P < 0.02). Gastrointestinal Side Effects Mild to moderate nausea and vomiting were the most frequently reported side effects. Withdrawal rates due to adverse events — primarily gastrointestinal — were 9.9% for liraglutide vs 3.8% for placebo. Most of the nausea and vomiting occurred early on, within the first 4 weeks, Dr. Pi-Sunyer told Medscape Medical News. "That's why you do a dose titration, starting with 0.6 mg and work your way up by 0.6-mg increments. Patients get better after 4 to 5 weeks. By 56 weeks, you have very few people who have a problem with [these side effects]." Rates of gallbladder disorders and pancreatitis were 2.7 and 0.3 events per 100 patient-years for liraglutide, respectively, and 1.1 and 0.1 events per 100 patient-years for placebo, respectively. Both pancreatitis and gallbladder-related problems were reported in 1 patient in the liraglutide group and 1 patient in the placebo group. The new framework for treating obesity as a chronic disease, previously reported on by Medscape Medical News , requires as much focus on obesity as on diabetes, said Dr. Zangeneh. Lifestyle modifications and medical therapy are needed for both conditions, he said. "Everything in medicine [has a] risk/benefit ratio. To leave people obese is not without risk."
May 21, 2014 (Healio) - Increasing severity of HF was associated with increased risk for the development of diabetes in a new study. However, researchers found that use of renin-angiotensin system inhibitors may attenuate the risk for diabetes. A previous study by the same research team demonstrated an increased risk for diabetes in patients with HF after MI. The new study was performed to analyze the risk for diabetes among all patients with HF, regardless of MI. Malene N. Demant, MD, from Copenhagen University Hospital Gentofte in Denmark, and colleagues followed all Danish patients discharged from first-time hospitalization for HF between 1997 and 2010 who had not previously used hypoglycemic agents (n=99,362). They estimated severity of HF by loop-diuretic dosage 90 days after discharge. Patients were stratified into five dosage groups: no loop diuretics (31%); =40 mg/day (25%); >40 mg/day to 80 mg/day (17%); >80 mg/day to 159 mg/day (12%); and =160 mg/day (15%). Follow-up occurred until a claimed prescription for an oral diabetes drug, death or the end of 2010. During follow-up, 8% of all patients developed diabetes and 63% of all patients died. Loop-diuretic dosage was associated with increased risk for developing diabetes in a dose-dependent manner. The researchers also reported that use of renin-angiotensin system inhibitors attenuated the risk for developing diabetes (P<.0001). Compared with patients using no loop diuretics, the adjusted HRs for other patients were as follows: -Patients taking =40 mg/day: HR=1.16 (95% CI, 1.07-1.26) with use of renin-angiotensin system inhibitors; HR=2.06 (95% CI, 1.83-2.32) without. -Patients taking >40 mg/day to 80 mg/day: HR=1.35 (95% CI, 1.24-1.46) with use of renin-angiotensin system inhibitors; HR=2.28 (95% CI, 2.01-2.59) without. -Patients taking >80 mg/day to 159 mg/day: HR=1.48 (95% CI, 1.35-1.62) with use of renin-angiotensin system inhibitors; HR=2.88 (95% CI, 2.52-3.3) without. -Patients taking =160 mg/day: HR=1.76 (95% CI, 1.61-1.92) with use of renin-angiotensin system inhibitors; HR=3.02 (95% CI, 2.66-3.43) without. "It might be that the sickest patients are those who develop diabetes," Demant said in a press release. "Thus, diabetes may, in part, be a marker of [HF] severity in addition to being a causal risk factor for mortality in [HF] cohorts."
One in Ten AMI Patients Have Unrecognized Incident Diabetes
Two New LDL Cholesterol Drugs May Have Big Impact on Heart Disease
COBA Conference Steers Forward in the Fight Against Childhood Obesity
Google Secures Patent for Glucose-Sensing Contact Lens
Medtronic to Use GlucoSitter Artificial Pancreas Software in Future Insulin Pumps - A Big Deal!